



Biosergen publishes interim report for fourth quarter 2022

Friday, March 31, 2023: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the fourth quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net)

Summary of the Interim Report for Q4 2022

TSEK	2022 Oct-Dec	2021 Oct-Dec	2022 Jan-Dec	2021 Jan-Dec
Other income	1.964	3.290	5.183	8.573
Profit/loss before depreciation (EBITDA)	-12.491	-9.876	-39.987	-34.077
Operating profit/loss before net financials	-12.491	-9.876	-39.987	-34.077
Net financials	87	-83	109	-240
Netprofit/loss for the period	-12.432	-9.959	-39.906	-34.318
Earnings per share (SEK)	-0,40	-0,35	-1,28	-1,22

Highlights during Q4 2022

- October 4, Biosergen announces the outcome in the rights issue
- December 12, The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005.

Highlights after the period

- January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.
- March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
- March 29, Biosergen provides Phase 2 clinical development strategy update.

The Financial report can be found on our website: <http://biosergen.net/investors/filings>

Annual Report

The annual report was planned to be published on April 6. It will now be disclosed on May 10 due to the work with the annual report has taken longer time than previously expected.

Biosergen will convene its Annual General Meeting May 31.

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net

Certified Adviser

Erik Penser Bank
Telefon: +46 8 463 8000
E-mail: certifiedadvisor@penser.se

ABOUT BIOSERGEN

Biosergen is a clinical stage biotechnology company that employs all its organizational and financial resources on the clinical development of BSG005. BSG005, a polyene macrolide, is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, and being completely free of the kidney toxicity hampering other drugs in its class. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care. The Company is also developing BSG005 *Nano* where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 *Nano Oral* is an extension of BSG005 *Nano*. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen is granted orphan drug status for BSG005 in the United States.